Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATH-097 SAD Study in Healthy Participants
NCT07640269Phase 1Not yet recruiting
- Sponsor
- Atheron Therapeutics
- Start
- Jul 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing ATH-097 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events at 8 days. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
ATH-097
Beyond the preview
Go deeper on NCT07640269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07640269.